Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Hochberg

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Leukemia & Lymphoma|February 13, 2018
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literatureRachael R Schulte, Manasi V Madiwale, Allyson Flower, et al.
Eclinicalmedicine|July 11, 2025
Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trialJessica Hochberg, Javier Oesterheld, Aliza Gardenswartz, et al.
Journal for Immunotherapy of Cancer|May 18, 2022
Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trialJessica Hochberg, Jaclyn Basso, Qiuhu Shi, et al.
Oncotarget|August 28, 2020
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBLYaya Chu, Aradhana Awasthi, Sanghoon Lee, et al.
Leukemia & Lymphoma|October 19, 2022
Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphomaAliza Gardenswartz, Brinda Mehta, Nader Kim El-Mallawany, et al.
Bone Marrow Transplantation|June 15, 2018
The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemiaJessica Hochberg, Stacey Zahler, Mark B Geyer, et al.
The Lancet. Haematology|November 19, 2023
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trialSarah H O'Brien, Vilmarie Rodriguez, Glen Lew, et al.
Leukemia|May 4, 2021
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphomaStan Goldman, Matthew Barth, Bruce Shiramizu, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Leukemia & Lymphoma|February 13, 2018
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literatureRachael R Schulte, Manasi V Madiwale, Allyson Flower, et al.
Eclinicalmedicine|July 11, 2025
Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trialJessica Hochberg, Javier Oesterheld, Aliza Gardenswartz, et al.
Journal for Immunotherapy of Cancer|May 18, 2022
Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trialJessica Hochberg, Jaclyn Basso, Qiuhu Shi, et al.
Oncotarget|August 28, 2020
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBLYaya Chu, Aradhana Awasthi, Sanghoon Lee, et al.
Leukemia & Lymphoma|October 19, 2022
Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphomaAliza Gardenswartz, Brinda Mehta, Nader Kim El-Mallawany, et al.
Bone Marrow Transplantation|June 15, 2018
The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemiaJessica Hochberg, Stacey Zahler, Mark B Geyer, et al.
The Lancet. Haematology|November 19, 2023
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trialSarah H O'Brien, Vilmarie Rodriguez, Glen Lew, et al.
Leukemia|May 4, 2021
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphomaStan Goldman, Matthew Barth, Bruce Shiramizu, et al.
Pageof 3